Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

233.95INR
11:22am BST
Change (% chg)

Rs-8.95 (-3.68%)
Prev Close
Rs242.90
Open
Rs242.50
Day's High
Rs244.00
Day's Low
Rs233.00
Volume
2,792,438
Avg. Vol
2,267,569
52-wk High
Rs432.50
52-wk Low
Rs233.00

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Unit Zydus Gets FDA Nod For Chlorthalidone Tablets
Monday, 13 May 2019 

May 13 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR CHLORTHALIDONE TABLETS USP.TABLETS WILL BE MANUFACTURED AT THE GROUP'S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets Final U.S. FDA Approval For Acetazolamide Injection
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM U.S. FDA FOR ACETAZOLAMIDE FOR INJECTION.  Full Article

Cadila Healthcare Says Zydus Gets Tentative USFDA Nod For Lacosamide Tablets
Monday, 8 Apr 2019 

April 8 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR LACOSAMIDE TABLETS.DRUG WILL BE MANUFACTURED AT THE GROUP'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD .LACOSAMIDE IS AN ANTICONVULSANT OR ANTIEPILEPTIC DRUG, USED TO PREVENT AND CONTROL SEIZURES.  Full Article

Cadila Healthcare Says U.S FDA Inspects Formulations Manufacturing Facility At Pharmez
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Cadila Healthcare Ltd ::U.S FDA INSPECTED CO‘S FORMULATIONS MANUFACTURING FACILITY LOCATED AT PHARMEZ, AHMEDABAD.INSPECTION CONCLUDED WITH ONE OBSERVATION.  Full Article

Cadila Healthcare Says Zydus Got USFDA Nod For Mirabegron Extended-Release Tablets
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR MIRABEGRON EXTENDED-RELEASE TABLETS.  Full Article

Cadila Healthcare Says Zydus Gets Final Approval From U.S FDA For Ambrisentan Tablets
Friday, 29 Mar 2019 

March 29 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM U.S FDA FOR AMBRISENTAN TABLETS.SAYS DRUG WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Acyclovir Ointment
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR ACYCLOVIR OINTMENT.SAYS ACYCLOVIR, AN ANTIVIRAL DRUG, WILL BE MANUFACTURED AT THE GROUP'S TOPICAL MANUFACTURING FACILITY AT AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Sitagliptin And Metformin Hydrochloride Extended-Release Tablets
Thursday, 14 Mar 2019 

March 14 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM THE USFDA FOR SITAGLIPTIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.SAYS DRUG WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare says Zydus Receives U.S. FDA Approval For Transdermal Product
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES USFDA APPROVAL FOR ITS TRANSDERMAL PRODUCT, RIVASTIGMINE TRANSDERMAL SYSTEM.GROUP ALSO RECEIVED FINAL APPROVAL FOR ROSUVASTATIN TABLETS USP IN STRENGTHS OF 5 MG, 10 MG, 20 MG, & 40 MG.  Full Article

Cadila Healthcare Vaccine Vaxirab N Gets Prequalification From WHO
Friday, 15 Feb 2019 

Feb 15 (Reuters) - Cadila Healthcare Ltd ::PURIFIED CHICK EMBRYO CELL RABIES VACCINE, VAXIRAB N, HAS RECEIVED PREQUALIFICATION FROM WORLD HEALTH ORGANISATION.  Full Article

Indian shares skid on renewed fears of US-China trade spat

May 6 Indian shares fell on Monday, in line with tumbling Asian markets, after U.S. President Donald Trump threatened to raise tariffs on $200 billion worth of Chinese goods, casting doubts over talks this week that were largely expected to reach a trade accord.